Instrument Inactif

Autres langues Medgenics, Inc. NYSE

Actions

US58436Q2030

Recherche biotechnologique et médicale

Cours en clôture NYSE
- ^USD	-

29/11/18	Transcript : Aevi Genomic Medicine, Inc. - Special Call
13/03/18	Transcript : Aevi Genomic Medicine, Inc., Q4 2017 Earnings Call, Mar 13, 2018

Autres langues

04/02/20	Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index
03/02/20	Aevi Genomic Medicine, Inc. Announces Resignation of Directors
03/02/20	AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
03/02/20	Aevi Genomic Medicine, LLC(NasdaqCM:GNMX) dropped from NASDAQ Composite Index
03/02/20	Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc..
23/12/19	AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)
11/12/19	AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)
10/12/19	AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
05/12/19	AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
22/11/19	Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial
22/11/19	AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)
20/11/19	AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)
14/11/19	Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
14/11/19	Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million.
15/10/19	Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination
13/08/19	Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
07/08/19	Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18)
07/08/19	Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
06/08/19	Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference
15/07/19	Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
24/06/19	Declaration of Voting Results by Aevi Genomic Medicine, Inc.
21/05/19	Aevi Genomic Medicine, Inc. Announces Executive Changes
14/05/19	Aevi Genomic Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019
29/03/19	The Children’s Hospital Nominates Board Candidate to Aevi Genomic
29/03/19	Aevi Genomic Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018